<DOC>
	<DOCNO>NCT02188303</DOCNO>
	<brief_summary>LY2944876 investigative drug treatment Type 2 Diabetes Mellitus . Part A study ass safety tolerability single dos LY2944876 Japanese participant . Participation expect last 7 week , include screen . Part B study investigate safety tolerability multiple dos LY2944876 non Japanese participant . Participation expect last 8 week , include screen . All dos administer injection fatty layer beneath skin . Screening require within 28 day prior start study . All participant attend post study safety assessment approximately 6 week final dose .</brief_summary>
	<brief_title>A Study LY2944876 Healthy Japanese Non-Japanese Participants</brief_title>
	<detailed_description />
	<criteria>Healthy male female participant Are first generation Japanese participant ( Part A ) nonJapanese participant ( Part B ) Have body mass index ( BMI ) 18.5 30 kilogram per meter square ( kg/m^2 ) , inclusive , Part A BMI 25 40 kg/m^2 , inclusive , Part B screen Have normal blood pressure heart rate ( approximately 5 minute supine approximately 2 minute stand ) determine investigator screen Have know allergy LY2944876 , related compound component formulation , history significant atopy Have abnormality 12lead electrocardiogram ( ECG ) screen and/or baseline , opinion investigator , increase risk associate participate study Have significant history current cardiovascular , respiratory , hepatic , renal , gastrointestinal ( GI ) , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have history acute chronic pancreatitis elevation serum lipase and/or amylase great 2 time upper limit normal ( ULN ) screen and/or baseline Have know ongoing psychiatric disorder consider clinically significant opinion investigator Have undergone form bariatric surgery Have fast blood glucose level great equal ( ≥ ) 7 millimoles per liter ( mmol/L ) ( ≥126 milligram per deciliter ( mg/dL ) ) screen Have fast triglyceride level ≥300 mg/dL ( 3.4 mmol/L ) screening Have obvious clinical sign symptom liver disease , acute chronic hepatitis , alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) level great ( &gt; ) 2.5 time ULN screen and/or baseline Have use intend use medication promote weight loss , within 3 month prior screen , duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>